Mabwell Passes On-site GMP Inspection by Regulatory Authority of PIC/S Member Country (Jordan) for the First Time
SHANGHAI, April 21, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its wholly-owned subsidiary, T-mab, has successfully passed the on-site GMP inspection conducted by the Jordan Food and Drug Administration (JFDA). The inspection covered two denosumab injections: 9MW0311 (Prolia® biosimilar) and 9MW0321 (Xgeva® biosimilar). The facility was granted conclusion of...
AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
SAN DIEGO, April 20, 2026 /PRNewswire/ -- Abogen, a clinical-stage biotechnology company focused on RNA innovation, today announced preliminary clinical results from the first-in-human (FIH) study of ABO2203 in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The data were presented in an oral session delivered at the AACR Annual Meeting 2026 in San Diego by Professor Li Wang...
Datasea Intelligent Technology Ltd. Completes Delivery of Three AI Multimodal Solution Projects with Aggregate Contract Value of Approximately USD 1.01 Million
Completed Projects Further Support the Company's Transition Toward High-Margin, Solution-Driven Revenue and Strengthen Customer Stickiness Across AI Multimodal Application Scenarios BEIJING, April 20, 2026 /PRNewswire/ -- Datasea Intelligent Technology Ltd. (NASDAQ: DTSS) ("Datasea" or the "Company"), a technology company specializing in AI-powered multimodal digital solutions and acoustic high-tech innovation, today announced...
Seegene Introduces STAgora at ESCMID Global 2026, Highlighting Real-Time Data with Automated PCR Workflows
The company highlights its approach to integrating real-time data analytics with automated PCR infrastructure The standalone booth features STAgora simulation and an interactive touchscreen experience An enhanced CURECA model is presented, illustrating next-generation automated laboratory workflows Strong on-site engagement from global healthcare and laboratory professionals, researchers, and industry stakeholders ...
Pinnacle Food Group Limited Announces Entry Into a Non-Binding MOU to Explore Establishing an Open Yeast Platform Hub in Hong Kong
VANCOUVER, BC and HONG KONG, April 20, 2026 /PRNewswire/ -- Pinnacle Food Group Limited (Nasdaq: PFAI), a technology-driven company operating at the intersection of smart agriculture and bio-engineering, today announced that its subsidiary, Pinnacle Food AgTech HK Limited (PFHK), has entered into a non-binding memorandum of understanding (MOU) with Open Yeast Collection...
TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region
With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one owner Advancing felzartamab – a CD38-directed antibody with potential broad applicability across a range of immune-mediated conditions – in the Greater China Region presents an important opportunity in a key global market Agreement builds on TJ Biopharma's development success...
Covation Biomaterials’ First Commercial Plant for bioTHF and bioPTMEG Reaches Mechanical Completion; Xatryx®，Brand Unveiled for New Non-Food bioPTMEG
SHANGHAI, April 20, 2026 /PRNewswire/ -- Covation Biomaterials LLC ("CovationBio®"), a biomaterials company with advanced technology in the bio-based materials industry, announced today that its first commercial plant for the C4 product platform, including bioTHF and bio-based polytetramethylene ether glycol ("PTMEG"), achieved mechanical completion in April 2026. In addition, CovationBio now officially launches the Xatryx® brand for the portfolio of new, non-food,...
Immunofoco Presents Preclinical Data for IMV102, an In Vivo CAR-T Candidate, Demonstrating Durable Tumor Control at the AACR 2026
SHANGHAI, April 20, 2026 /PRNewswire/ -- Immunofoco today announced the presentation of new preclinical data for its in vivo BCMA-targeting CAR-T candidate, IMV102, at the AACR Annual Meeting 2026. The data demonstrate that IMV102 achieved potent and durable anti-tumor activity in multiple myeloma models, highlighting its potential to address key limitations of conventional CAR-T therapies. Autologous CAR-T therapy has...
Fapon Biopharma Presents at AACR Annual Meeting 2026, Showcasing Core Technology Platforms and Advancing Pipeline
SAN DIEGO, April 20, 2026 /PRNewswire/ -- Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, is pleased to announce its participation in the AACR Annual Meeting 2026, taking place April 19–22, 2026 in San Diego, California. At the meeting, the company is exhibiting at Booth No.3856 and presenting...
AlphaGen Therapeutics to Present Preclinical Studies of Two Next-Generation Alpha Therapies at AACR 2026
SHANGHAI, April 20, 2026 /PRNewswire/ -- AlphaGen Therapeutics (AlphaGen), a biopharmaceutical company that focuses on developing next-generation targeted alpha radiotherapies, today announced that it will present preclinical data on two advanced radiopharmaceutical programs at the 2026 Annual Meeting of the American Association for Cancer Research (AACR), is being held in San Diego, California, from April 17–22. Pb-AG1002 is a...
